NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company based in the San Francisco Bay Area, is focused on developing effective treatments that relieve chronic pain and improve quality of life. NGX-4010, the company’s leading product candidate, could possibly revolutionize the treatment of neuropathic pain as a single application may provide months of relief. The product candidate is currently in Phase 3 clinical trials. For further information, visit the Company’s web site at www.neurogesx.com
- 18 years ago
QualityStocks
NeurogesX, Inc. (NASDAQ: NTII)
Tags Rodman & Renshaw
Related Post
-
Metalsource Mining Inc. (CSE: MSM) (OTCQB: MSMMF) (FSE: E9Z) Extends Silver Hill Drilling South as It Prepares for Larger Exploration Tests
Disseminated on behalf of Metalsource Mining Inc. and may include paid advertising. Metalsource Mining, advancing…
-
As Major Gold Discoveries Become Scarcer, Lahontan Gold Advances a Past-Producing Nevada Asset
Disseminated on behalf of Lahontan Gold Corp. and may include paid advertising. A shrinking pipeline…
-
Military Drone Spending Is Surging into Airspace Where GPS Can No Longer Be Trusted
Disseminated on behalf of SPARC AI Inc. and may include paid advertising. The Pentagon’s fiscal…